CRIS Current Research Information System

LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.044
EU - Europa 3.008
AS - Asia 1.596
AF - Africa 177
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 9
OC - Oceania 7
Totale 9.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.026
GB - Regno Unito 845
CN - Cina 593
SE - Svezia 557
SG - Singapore 439
IT - Italia 382
DE - Germania 375
VN - Vietnam 218
IN - India 191
UA - Ucraina 175
IE - Irlanda 146
FR - Francia 117
RU - Federazione Russa 111
TG - Togo 69
ZA - Sudafrica 65
JO - Giordania 61
EE - Estonia 56
CH - Svizzera 54
BG - Bulgaria 53
FI - Finlandia 43
BE - Belgio 35
IR - Iran 23
JP - Giappone 22
CA - Canada 18
CI - Costa d'Avorio 18
EU - Europa 17
NL - Olanda 14
SC - Seychelles 13
MY - Malesia 11
TR - Turchia 11
ES - Italia 10
NG - Nigeria 8
AU - Australia 7
GR - Grecia 7
PL - Polonia 7
BR - Brasile 6
LB - Libano 6
HK - Hong Kong 5
ID - Indonesia 5
AT - Austria 4
TH - Thailandia 3
TW - Taiwan 3
CL - Cile 2
CZ - Repubblica Ceca 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
LT - Lituania 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
EG - Egitto 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MA - Marocco 1
MD - Moldavia 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
Totale 9.859
Salva come PNG Salva come JPEG
Città #
Southend 752
Fairfield 640
Chandler 531
Houston 451
Singapore 391
Ashburn 389
Woodbridge 301
Seattle 261
Wilmington 240
Ann Arbor 236
Santa Clara 202
Cambridge 201
Princeton 190
Dublin 146
Dong Ket 134
Boardman 116
Jacksonville 106
Westminster 75
Nanjing 71
Lomé 69
Padova 68
Amman 61
Bologna 57
Beijing 55
New York 53
Sofia 53
Bern 45
Bremen 45
Jinan 44
Berlin 43
Helsinki 42
San Diego 42
Shenyang 39
Brussels 35
Saint Petersburg 34
Hyderabad 32
Turin 28
Redmond 27
Tianjin 27
Milan 25
Guangzhou 24
Jiaxing 21
Mülheim 21
Hebei 20
Abidjan 18
Nanchang 18
Tokyo 18
Zhengzhou 18
Florence 17
Norwalk 17
Changsha 16
Los Angeles 15
Dearborn 13
Mahé 13
Medford 13
Shanghai 13
Taiyuan 12
Kuala Lumpur 11
Falls Church 10
Ningbo 10
Toronto 10
Des Moines 9
Hangzhou 9
Leawood 9
Verona 9
Abeokuta 8
Haikou 8
Redwood City 8
Changchun 7
Fremont 7
Fuzhou 7
Istanbul 7
London 7
Phoenix 7
Rome 7
Washington 7
Wuhan 7
Zanjan 7
Foshan 6
Frankfurt am Main 6
San Francisco 6
Amsterdam 5
Bühl 5
Chengdu 5
Chicago 5
Jakarta 5
Kunming 5
Lanzhou 5
Madrid 5
Paris 5
Pune 5
Qingdao 5
San Venanzo 5
Shenzhen 5
São Paulo 5
Xi'an 5
Andover 4
Frankfurt Am Main 4
Harbin 4
Hefei 4
Totale 6.924
Salva come PNG Salva come JPEG
Nome #
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 332
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 194
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 190
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 190
A novel model of CCl4-induced cirrosi with ascites in the mouse. 188
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 163
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 160
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 155
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 153
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 150
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 150
BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. 146
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 145
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 145
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 145
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 143
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 142
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 141
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 139
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 137
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 136
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 134
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 134
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 132
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. 129
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 129
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 129
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 127
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 127
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 127
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 125
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 124
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 124
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 123
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 123
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 122
Dendritic cell differentiation. 119
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 117
Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. 116
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 114
Stem cell mobilization and collection in patients with liver cirrhosis. 113
Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages. 112
Hematopoietic stem cell mobilization. 112
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 112
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 111
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 111
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. 109
Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. 109
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 109
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 107
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 106
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 106
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 105
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 102
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 102
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 102
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 101
null 97
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 94
More ADO about IDO: GVHD. 92
Stem cell plasticity: time for a reappraisal ? 90
CD 133+ stem cells for the treatment of end stage liver disease. 87
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 87
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 87
The CD47 pathway is deregulated in human immune thrombocytopenia 86
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 85
Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. 82
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 82
The sixth sense: Hematopoietic Stem Cells detect danger through purinergic signalling. 81
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 80
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 79
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 79
New strategies for stem cell mobilization 75
Pegfilgrastim for mobilization of stem cells in allogeneic donors. 72
The P2X7 receptor: a new player in IL-1 processing and release 70
Zoledronic acid modulates function and differentiation of myeloid cells. 66
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 66
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 64
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 62
Pre-emptive use of Plerixafor in hard-to-mobilize patients: An emerging concept. 61
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 61
Granulocyte colony-stimulating factor promotes the generation of regulatory DCs through induction of IL-10 and IFN-alfa. 56
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 55
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 54
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 46
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 37
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 34
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 33
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 30
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 28
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 26
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 25
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 24
Evaluation of immunotoxins containing single-chain ribosome- inactivating proteins and an anti-CD22 monoclonal antibody (OM124): In vitro and in vivo studies 19
Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: In vitro results and in vivo effects in an acute rejection model 14
In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins 13
Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation 11
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. 10
Mobilization with chemotherapy+G-CSF+Plerixafor in Europe: The Italian experience. 2
Totale 10.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.151
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.389 0 0 0 0 0 0 305 325 362 164 97 136
2020/20211.047 241 84 21 61 22 57 12 64 109 74 55 247
2021/20221.777 135 79 103 180 141 100 48 123 54 163 339 312
2022/20232.020 257 289 107 266 120 166 65 92 348 52 138 120
2023/2024545 45 79 42 77 58 130 34 22 7 21 12 18
2024/20251.199 85 306 163 210 327 98 10 0 0 0 0 0
Totale 10.050